Gilead Sciences
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell GILD and other ETFs, options, and stocks.About GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
GILD Key Statistics
GILD News
Gilead Sciences (NASDAQ:GILD) First Quarter 2024 Results Key Financial Results Revenue: US$6.69b (up 5.3% from 1Q 2023). Net loss: US$4.17b (down from US$1.0...
Loading... Loading... Deep-pocketed investors have adopted a bullish approach towards Gilead Sciences GILD, and it's something market players shouldn't ignore....
Gilead Sciences, Inc. GILD reported better-than-expected results in the first quarter, as its loss was narrower than expected and sales beat estimates. GILD’s...
Analyst ratings
56%
of 32 ratingsMore GILD News
Participants Andrew D. Dickinson; CFO; Gilead Sciences, Inc. Cindy Perettie; EVP of Kite; Gilead Sciences, Inc. Daniel P. O'Day; Chairman & CEO; Gilead Scien...
Total Revenue: Reached $6.7 billion in Q1 2024, a 5% increase year-over-year, exceeding estimates of $6.338 billion. Net Loss: Reported a significant net loss...
Gilead Sciences (GILD) came out with a quarterly loss of $1.32 per share versus the Zacks Consensus Estimate of a loss of $1.49. This compares to earnings of $1...
By Deena Beasley (Reuters) -Gilead Sciences reported a first-quarter loss on Thursday after taking a $3.9 billion charge for its recent acquisition of liver dr...
Gilead Sciences (GILD) beat Wall Street's first-quarter sales forecasts Thursday on the back of its Covid treatment, Veklury, but lighter-than-expected sales of...
Product Sales Excluding Veklury Increased 6% Year-Over-Year to $6.1 billion Biktarvy Sales Increased 10% Year-Over-Year to $2.9 billion Oncology Sales Increas...
Gilead Sciences (NASDAQ:GILD) is scheduled to announce Q1 earnings results on Thursday, April 25th, after market close. Analysts estimate a loss of $1.54 per s...